Skip to main content

Table 3 The blood purifications needed acute kidney injury cases in hematological malignancies

From: Methotrexate-induced acute kidney injury in patients with hematological malignancies: three case reports with literature review

Ref

Underlying disease

Listed risk factors

Age y.o

Sex

Baseline sCr mg/dL

Max. sCr mg/dL

Abrupt sCr increase

MTX dose g/m2

Max. MTX nmol/mL

Blood purification modalities

No. of times

HD

QB

HD

QD

HD

h

DESA

m2

CPDG2 use

6

ALL

NA

44

F

NA

NA

UK

1.0

62

HD

1

400

500

4

1.8

No

6

CLL

NA

72

M

NA

NA

UK

1.0

1.5

HD

1

300

500

4

1.8

No

10

DLBCL

NA

36

M

0.8

3.2

Yes

3.5

31

HD or HDF

8

150

NA

4

1.5

No

10

ALL

NA

45

M

0.7

1.8

Yes

3.0

23

ChH

9

No

10

ALL

NA

16

M

0.5

3.8

Yes

5.0

134

HD and ChH

3

180

NA

4

1.3

No

11

Histiocytoma

NA

39

NA

NA

2.6

UK

12

688

HD or HF

3

NA

NA

NA

NA

Yes

11

NHL

NA

10

NA

NA

4.7

UK

5.0

9.2

HD or HF

8

NA

NA

NA

NA

Yes

12

PCNSL

TAZ/PIPC

58

M

0.7

3.1

Yes

2.5

93

ChH

4

Yes

12

ALbL

Gemfibrozil

39

M

0.7

6.0

Yes

3.0

41

ChH

4

Yes

13

NHL

NA

35

M

1.0

3.0

Yes

6.01

37

PE or CHDF

11

No

14

PCNSL

NA

68

F

0.8

5.2

Yes

3.0

22

HD

2

NA

NA

NA

NA

Yes

*

ALbL

Lansoprazole cefepime

48

M

0.7

7.6

Yes

3.0

33

PE and/or HD

8

150

500

3

1.3

No

*

MPAL

Cefepime doripenem

19

M

0.6

6.9

Yes

3.0

9.5

PE or HD or ChH

5

150

500

3

1.3

No

*

PCNSL

UTI

72

F

0.5

2.0

Yes

2.0

7.7

PE and/or HD

7

150

500

3

1.1

No

  1. Risk factors are known to affect MTX clearance besides pre-performed chemotherapy
  2. *Reported in this paper; 1 per whole body
  3. y.o years old, Max. maximum, MTX methotrexate, No. number, HD hemodialysis, QB blood flow (mL/min), QD dialysate flow (mL/min), DESA dialyzer effective surface area (m2), CPDG2 carboxypetidase-G2, NA not available, UK unknown, CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, ALL acute lymphocytic leukemia, NHL non-Hodgkin lymphoma, PCNSL primary central nervous system lymphoma, ALbL acute lymphoblastic leukemia, MPAL mixed-phenotype acute leukemia, TAZ/PIPC tazobactam/ piperacillin, UTI urinary tract infection, ChH charcoal hemoperfusion, HDF hemodiafiltration, HF hemofiltration, PE plasma exchange, CHDF continuous hemodiafiltration